BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
(NASDAQ:BBIO), The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturity Offering priced at 0.75% interest rate and 45% conversion premium PALO ALTO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a new type of biopharmaceutical company focused […]